Abstract:To investigate the cellular target selectivity of small molecules targeting thioredoxin reductase 1,we reported the construction and functional research of a stable TrxR1 gene (encode thioredoxin reductase 1) knockout HCT-116 cell line.We designed and selected TrxR1 knockout sites according to the TrxR1 gene sequence and CRISPR/Cas9 target designing principles.SgRNA oligos based on the selected TrxR1 knockout sites were obtained.Next,we constructed knockout plasmid by cloning the sgRNA into the pCasCMV-Puro-U6 vector.After transfection of the plasmid into HCT-116 cells,TrxR1 knockout HCT-116 cells were selected using puromycin resistance.The TrxR1 knockout efficiency was identified and verified by DNA sequencing,immunoblotting,TRFS-green fluorescent probe,and cellular TrxR1 enzyme activity detection.Finally,the correlation between TrxR1 expression and cellular effects of drugs specifically targeting TrxR1 was investigated by CCK-8 assay.The results demonstrated that the knockout plasmid expressing the sgRNA effectively knocked-out TrxR1 gene within HCT-116 cells,and no expression of TrxR1 protein could be observed in stable TrxR1 knockout HCT-116(HCT116-TrxR1-KO) cells.The TrxR1-targeting inhibitor auranofin did not show any inhibitory activity against either cellular TrxR1 enzyme activity or cell proliferation.Based on these results,we conclude that a stable TrxR1 gene knockout HCT-116 cell line was obtained through CRISPR/Cas9 techniques,which may facilitate investigating the role of TrxR1 in various diseases.